Omic and Multidimensional Spatial (OMS) Atlas

The OMS Atlas Center based at the Oregon Health Sciences University (OHSU) and led by Joe Gray is a component of the National Cancer Institute Human Tumor Atlas Network (HTAN), a multi-center program within the National Cancer Institute that emerged from the Beau Biden Cancer Moonshot Initiative. Our team us a collaborator on the OMS Atlas focusing on the application of multi-dimensional CyCIF imaging methods to clinical trial samples.

The OMS is focused on elucidating mechanisms of therapy resistance in three clinical scenarios in which disease recurrence is a major concern: (a) hormone-receptor positive breast cancer (HRBC) undergoing treatment with a CDK4/6 inhibitor in combination with endocrine therapy, (b) triple negative breast cancer (TNBC) undergoing treatment with a PARP inhibitor and an immunomodulatory agent (c) castration resistance prostate cancer (CRPC) undergoing treatment with enzalutamide. Diverse imaging and omic methods are being applied to this analysis including several complementary ways to create spatial maps of cell types and states. These include multiplex immuno-histochemistry, CyCIF, Focused Ion Beam Scanning Electron Microscope (FIB-SEM).

Funding: The OMS Center at Harvard Medical School is funded by a Human Tumor Atlas Network grant U2C-CA233280 (Joe Gray PI) from the National Cancer Institute Omic and Multidimensional Spatial (OMS) Atlas”.

Harvard Program in Therapeutic Science

Armenise Building

210 Longwood Ave

Boston, MA 02115


Funded by NIH grants P50-GM107618, U54-HL127365, U2C-CA233262, U2C-CA233280, U54-CA225088, the Ludwig Center at Harvard, and the Ludwig Cancer Research Foundation
©2020, Laboratory of Systems Pharmacology. All rights reserved.
Please cite this resource as, RRID:SCR_016267